Literature DB >> 10675401

Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene.

G Andrei1, R Snoeck, E De Clercq, R Esnouf, P Fiten, G Opdenakker.   

Abstract

Drug-resistant strains of herpes simplex virus type 1 (HSV-1) were selected under the pressure of (S)-3-hydroxy-2-phosphonylmethoxypropyl (HPMP) derivatives of cytosine (HPMPC, cidofovir) and adenine (HPMPA) and 2-phosphonylmethoxyethyl (PME) derivatives of adenine (PMEA, adefovir) and 2,6-diaminopurine (PMEDAP). HPMPC-resistant (HPMPC(r)) and HPMPA(r) strains were cross-resistant to one another, but they remained sensitive to foscarnet (PFA), acyclovir (ACV) and the PME derivatives, while the PMEA(r) and PMEDAP(r) strains showed cross-resistance to PFA and ACV. The PMEA(r), PMEDAP(r) and PFA(r) mutants all revealed a single nucleotide change resulting in a Ser-724 to Asn mutation within the conserved region II of the DNA polymerase. Two HPMPA(r) clones and one HPMPC(r) clone possessed single amino acid changes in the DNA polymerase (HPMPA(r) clone D1, Leu-1007 to Met; HPMPA(r) clone B5, Ile-1028 to Thr; HPMPC(r) clone C3, Val-573 to Met). The HPMPC(r) clone A4 contained two mutations, Ala-136 to Thr and Arg-700 to Met. The mutation at position 136, located outside the catalytic domain of the enzyme, was not detected in other HPMPC(r) clones, suggesting that this mutation may not be responsible for the resistant phenotype. Residue 573 is located within the 3'-->5' exonuclease editing domain close to the catalytically important residues Tyr-577 and Asp-581. Similarly, residue 700 is located in the palm subdomain of the catalytic domain, adjacent to the Asp residues 717, 886 and 888 that are vital for polymerase activity. The HPMPA(r) mutations at residues 1007 and 1028, beyond the last conserved region, still fall within the thumb subdomain of the catalytic domain. The different drug-resistant mutants varied in neurovirulent behaviour, the HPMPC(r) strains showing reduced neurovirulence compared with the wild-type.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10675401     DOI: 10.1099/0022-1317-81-3-639

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  14 in total

1.  Evaluating phenotype and genotype of drug-resistant strains in herpesviruses.

Authors:  G Andrei; P Fiten; E De Clercq; R Snoeck; G Opdenakker
Journal:  Mol Biotechnol       Date:  2001-06       Impact factor: 2.695

Review 2.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.

Authors:  Graciela Andrei; Don B Gammon; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck; David H Evans
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin.

Authors:  Graciela Andrei; Jan Balzarini; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Mutations conferring resistance to viral DNA polymerase inhibitors in camelpox virus give different drug-susceptibility profiles in vaccinia virus.

Authors:  Sophie Duraffour; Graciela Andrei; Dimitri Topalis; Marcela Krečmerová; Jean-Marc Crance; Daniel Garin; Robert Snoeck
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

6.  Topical tenofovir, a microbicide effective against HIV, inhibits herpes simplex virus-2 replication.

Authors:  Graciela Andrei; Andrea Lisco; Christophe Vanpouille; Andrea Introini; Emanuela Balestra; Joost van den Oord; Tomas Cihlar; Carlo-Federico Perno; Robert Snoeck; Leonid Margolis; Jan Balzarini
Journal:  Cell Host Microbe       Date:  2011-10-20       Impact factor: 21.023

7.  Organotypic epithelial raft cultures as a model for evaluating compounds against alphaherpesviruses.

Authors:  Graciela Andrei; Joost van den Oord; Pierre Fiten; Ghislain Opdenakker; Chris De Wolf-Peeters; Erik De Clercq; Robert Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

Review 8.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

9.  Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids.

Authors:  Julie Bestman-Smith; Guy Boivin
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

10.  The use of nerve growth factor in herpetic keratitis: a case report.

Authors:  Cellini Mauro; Leonetti Pietro; Campos C Emilio
Journal:  J Med Case Rep       Date:  2007-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.